azd-9056
Small moleculeexperimental
Clinical trial activity
5 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2007 (NCT00520572)
Timeline
Indications
Mechanism of action
- P2X purinoceptor 7ANTAGONIST
P2RX7 antagonist
Compound is listed in AstaZeneca's clinical and/or preclinical compound bank and available for research projects (http://openinnovation.astrazeneca.com/what-we-offer/compound/azd9056/).
Chemistry & pharmacology
Loading structure…
SMILES
O=C(NCC12CC3CC(CC(C3)C1)C2)c1cc(CCCNCCCO)ccc1Cl- Mol. weight
- 419.01 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3545108 ↗
Also known as
- azd9056
- azd9056
- azd9056
- azd-9056
- azd-9056
- azd-9056
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00908934 | Phase 1 | May 1, 2009 | AstraZeneca, ICON |
| NCT00920608 | Phase 1 | May 1, 2009 | AstraZeneca |
| NCT00736606 | Phase 1 | Aug 1, 2008 | AstraZeneca, Parexel |
| NCT00700986 | Phase 1 | Jun 1, 2008 | AstraZeneca |
| NCT00520572 | Phase 2 | Aug 1, 2007 | AstraZeneca, Icahn School of Medicine at Mount Sinai, Theorem Clinical Research |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AstraZeneca | For profit | 5 | 5 | 2 | 2007 |
| Icahn School of Medicine at Mount Sinai | Academic/Hospital | 1 | 0 | 1 | 2007 |
| ICON | For profit | 1 | 0 | 1 | 2009 |
| Parexel | For profit | 1 | 0 | 1 | 2008 |
| Theorem Clinical Research | For profit | 1 | 0 | 1 | 2007 |
5 organizations
Page 1 / 1